Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Bend Memorial Clinic

Neither a doctor nor a teaching hospital

Research payments

$194,772

26 payments

Through program year 2025, Bend Memorial Clinic is reported as receiving $194,772 in research payments, across 26 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $108,895 11
2024 Research $13,566 1
2023 Research $24,606 3
2022 Research $22,656 2
2021 Research $4,775 3
2020 Research $1,933 2
2019 Research $18,340 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Cumberland Pharmaceuticals, Inc. $96,490 9 payments
  2. Novartis Pharmaceuticals Corporation $67,094 7 payments
  3. Amgen Inc. $19,587 5 payments
  4. AbbVie, Inc. $6,140 1 payment
  5. Gilead Sciences, Inc. $3,500 1 payment
  6. Eli Lilly and Company $1,961 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (Ipf) $96,490 9 payments
  2. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $51,231 5 payments
  3. A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive LDL-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome $15,863 2 payments
  4. CFZ013 Weekly $13,500 1 payment
  5. Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome $6,140 1 payment
  6. A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma $3,500 1 payment
  7. Prospective Observational Study of Onpro vs SOC. $3,195 3 payments
  8. Prospective Observational Study of Onpro vs SOC $2,892 1 payment
  9. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $1,112 2 payments
  10. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 1) $849 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record